Role of digoxin in controlling the ventricular rate during atrial fibrillation: a systematic review and a rethinking

References

• Hauptman PJ, Kelly RA. Digitalis. Circulation. 1999;99(9):1265–1270.
   PubMed Web of Science ®Google Scholar
• Akera T, Brody TM. The role of Na+, K+-ATPase in the inotropic action of digitalis. Pharmacol Rev. 1977;29(3):187–220.
   PubMed Web of Science ®Google Scholar
• Wang L, Wible BA, Wan X, Ficker E. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking. J Pharmacol Exp Ther. 2007;320(2):525–534.
   Web of Science ®Google Scholar
• Opie LH. Digitalis, yesterday and today, but not forever. Circ Cardiovasc Qual Outcomes. 2013;6(5):511–513.
   Web of Science ®Google Scholar
• Lloyd MA, Sandberg SM, Edwards BS. Role of renal Na+, K(+)-ATPase in the regulation of sodium excretion under normal conditions and in acute congestive heart failure. Circulation. 1992;85(5):1912–1917.
   Web of Science ®Google Scholar
• Ross J Jr, Waldhausen JA, Braunwald E. Studies on digitalis. I. Direct effects on peripheral vascular resistance. J Clin Invest. 1960;39:930–936.
   Web of Science ®Google Scholar
• Stark JJ, Sanders CA, Powell WJ Jr. Neurally mediated and direct effects of acetylstrophanthidin on canine skeletal muscle vascular resistance. Circ Res. 1972;30(3):274–282.
   Web of Science ®Google Scholar
• Gillis RA. Digitalis: A neuroexcitatory drug. Circulation. 1975;52(5):739–742.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Adams KF Jr, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation. 2004;109(24):2959–2964.
   PubMed Web of Science ®Google Scholar
• Thames MD, Miller BD, Abboud FM. Sensitization of vagal cardiopulmonary baroreflex by chronic digoxin. Am J Physiol. 1982;243(5):H815–H818.
   Google Scholar
• Quest JA, Gillis RA. Effect of digitalis on carotid sinus baroreceptor activity. Circ Res. 1974;35:247–255.
   Web of Science ®Google Scholar
• Wang W, Chen JS, Zucker IH. Carotid sinus baroreceptor sensitivity in experimental heart failure. Circulation. 1990;81(6):1959–1966.
   Web of Science ®Google Scholar
• Ferrari A, Gregorini L, Ferrari MC, Preti L, Mancia G. Digitalis and baroreceptor reflexes in man. Circulation. 1981;63(2):279–285.
   Web of Science ®Google Scholar
• Krum H, Bigger JT Jr, Goldsmith RL, Packer M. Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure. J Am Coll Cardiol. 1995;25(2):289–294.
   Web of Science ®Google Scholar
• Kosowsky BD, Haft JI, Lau SH, Stein E, Damato AN. The effects of digitalis on atrioventricular conduction in man. Am Heart J. 1968;75(6):736–742.
   Web of Science ®Google Scholar
• Meijler FL. An “account” of digitalis and atrial fibrillation. J Am Coll Cardiol. 1985;5(5 Suppl A):60A–68A.
   Web of Science ®Google Scholar
• Riaz K, Forker AD. Digoxin use in congestive heart failure. Current status. Drugs. 1998;55(6):747–758.
   Web of Science ®Google Scholar
• Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol. 1993;22(4):955–962.
   PubMed Web of Science ®Google Scholar
• Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med. 1993;329(1):1–7.
   PubMed Web of Science ®Google Scholar
• Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525–533.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Patel K, Filippatos G, et al. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail. 2013;15(5):551–559.
   Web of Science ®Google Scholar
• Testani JM, Brisco MA, Tang WH, et al. Potential effects of digoxin on long-term renal and clinical outcomes in chronic heart failure. J Card Fail. 2013;19(5):295–302.
   Web of Science ®Google Scholar
• Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347(18):1403–1411.
   PubMed Web of Science ®Google Scholar
• Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006;27(2):178–186.
   PubMed Web of Science ®Google Scholar
• Eberhardt RT, Frishman WH, Landau A, et al. J Am Coll Cardiol. 1994;(Suppl A):A 100.
   Google Scholar
• Castagno D, Petrie MC, Claggett B, McMurray J. Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. Eur Heart J. 2012;33(9):1137–1141.
   Web of Science ®Google Scholar
• Flory JH, Ky B, Haynes K, et al. Observational cohort study of the safety of digoxin use in women with heart failure. BMJ Open. 2012;2(2):e000888.
   Web of Science ®Google Scholar
• Andrey JL, Romero S, García-Egido A, et al. Mortality and morbidity of heart failure treated with digoxin. A propensity-matched study. Int J Clin Pract. 2011;65(12):1250–1258.
   Web of Science ®Google Scholar
• Freeman JV, Yang J, Sung SH, Hlatky MA, Go AS. Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure. Circ Cardiovasc Qual Outcomes. 2013;6(5):525–533.
   Web of Science ®Google Scholar
• Lindsay SJ, Kearney MT, Prescott RJ, Fox KA, Nolan J. Digoxin and mortality in chronic heart failure. UK Heart Investigation. Lancet. 1999;354(9183):1003.
   Web of Science ®Google Scholar
• Ahmed A, Bourge RC, Fonarow GC, et al. Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure. Am J Med. 2014;127(1):61–70.
   Web of Science ®Google Scholar
• Moss AJ, Davis HT, Conard DL, DeCamilla JJ, Odoroff CL. Digitalis-associated cardiac mortality after myocardial infarction. Circulation. 1981;64(6):1150–1156.
   Web of Science ®Google Scholar
• Ryan TJ, Bailey KR, McCabe CH, et al. The effects of digitalis on survival in high-risk patients with coronary artery disease. The Coronary Artery Surgery Study (CASS). Circulation. 1983;67(4):735–742.
   Web of Science ®Google Scholar
• Just H, Drexler H, Taylor SH, Siegrist J, Schulgen G, Schumacher M. Captopril versus digoxin in patients with coronary artery disease and mild heart failure. A prospective, double-blind, placebo-controlled multicenter study. The CADS Study Group. Herz. 1993;18 Suppl 1:436–443.
   Google Scholar
• Hunt SA, Abraham WT, Chin MH, et al; American College of Cardiology Foundation; American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53(15):e1–e90.
   PubMed Web of Science ®Google Scholar
• Gjesdal K, Feyzi J, Olsson SB. Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data. Heart. 2008;94(2):191–196.
   Web of Science ®Google Scholar
• Hallberg P, Lindbäck J, Lindahl B, Stenestrand U, Melhus H; RIKS-HIA group. Digoxin and mortality in atrial fibrillation: a prospective cohort study. Eur J Clin Pharmacol. 2007;63(10):959–971.
   Web of Science ®Google Scholar
• Wyse DG, Waldo AL, DiMarco JP, et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825–1833.
   PubMed Web of Science ®Google Scholar
• Corley SD, Epstein AE, DiMarco JP, et al; AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004;109(12):1509–1513.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Fonarow GC, van Veldhuisen DJ, et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J. 2013;34(20):1489–1497.
   PubMed Web of Science ®Google Scholar
• Whitbeck MG, Charnigo RJ, Khairy P, et al. Increased mortality among patients taking digoxin – analysis from the AFFIRM study. Eur Heart J. 2013;34(20):1481–1488.
   PubMed Web of Science ®Google Scholar
• Roy D, Talajic M, Nattel S, et al; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358(25):2667–2677.
   PubMed Web of Science ®Google Scholar
• Friberg L, Hammar N, Rosenqvist M. Digoxin in atrial fibrillation: report from the Stockholm Cohort study of Atrial Fibrillation (SCAF). Heart. 2010;96(4):275–280.
   PubMed Web of Science ®Google Scholar
• Cully M. The dangers of digoxin in AF. Nat Rev Cardiol. 2013; 10(2):61.
   Google Scholar
• Hsu LF, Jaïs P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004;351(23):2373–2383.
   PubMed Web of Science ®Google Scholar
• Heinz G, Siostrzonek P, Kreiner G, Gössinger H. Improvement in left ventricular systolic function after successful radiofrequency His bundle ablation for drug refractory, chronic atrial fibrillation and recurrent atrial flutter. Am J Cardiol. 1992;69(5):489–492.
   Web of Science ®Google Scholar
• Rodriguez LM, Smeets JL, Xie B, et al. Improvement in left ventricular function by ablation of atrioventricular nodal conduction in selected patients with lone atrial fibrillation. Am J Cardiol. 1993;72(15):1137–1141.
   Web of Science ®Google Scholar
• Lemery R, Brugada P, Cheriex E, Wellens HJ. Reversibility of tachycardia-induced left ventricular dysfunction after closed-chest catheter ablation of the atrioventricular junction for intractable atrial fibrillation. Am J Cardiol. 1987;60(16):1406–1408.
   Web of Science ®Google Scholar
• Rawles JM. What is meant by a “controlled” ventricular rate in atrial fibrillation? Br Heart J. 1990;63(3):157–161.
   Google Scholar
• Atwood JE, Myers J, Sullivan M, et al. Maximal exercise testing and gas exchange in patients with chronic atrial fibrillation. J Am Coll Cardiol. 1988;11(3):508–513.
   PubMed Web of Science ®Google Scholar
• Fuster V, Rydén LE, Cannom DS, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(7):e257–e354.
   PubMed Web of Science ®Google Scholar
• Olshansky B, Rosenfeld LE, Warner AL, et al; AFFIRM Investigators. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004;43(7):1201–1208.
   PubMed Web of Science ®Google Scholar
• Van Gelder IC, Hagens VE, Bosker HA, et al; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 5, 2002;347(23):1834–1840.
   Google Scholar
• Van Gelder IC, Groenveld HF, Crijns HJ, et al; RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362(15):1363–1373.
   PubMed Web of Science ®Google Scholar
• European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, et al; ESC Committee for Practice Guidelines. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12(10):1360–1420.
   Web of Science ®Google Scholar
• Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011;57(11):e101–e198.
   PubMed Web of Science ®Google Scholar
• Lip GY, Hee FL. Paroxysmal atrial fibrillation. QJM. 2001;94(12):665–678.
   PubMed Web of Science ®Google Scholar
• Li-Saw-Hee FL, Lip GY. Digoxin revisited. QJM. 1998;91(4):259–264.
   Google Scholar
• Digoxin: serious drug interactions. Prescrire Int. 2010;19(106):68–70.
   Google Scholar
• Hooymans PM, Merkus FW. Current status of cardiac glycoside drug interactions. Clin Pharm. 1985;4(4):404–413.
   Google Scholar
• Chirinos JA, Castrellon A, Zambrano JP, et al. Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvalvular atrial fibrillation. Heart Rhythm. 2005;2(5):525–529.
   Web of Science ®Google Scholar
• Ahern TP, Lash TL, Sørensen HT, Pedersen L. Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study. Breast Cancer Res. 2008;10(6):R102.
   Web of Science ®Google Scholar
• Chan KE, Lazarus JM, Hakim RM. Digoxin associates with mortality in ESRD. J Am Soc Nephrol. 2010;21(9):1550–1559.
   PubMed Web of Science ®Google Scholar
• Juillière Y, Selton-Suty C. Digoxin therapy: A persisting interest despite contrary winds. Arch Cardiovasc Dis. 2010;103(5):281–284.
   Web of Science ®Google Scholar
• Newman RA, Yang P, Pawlus AD, Block KI. Cardiac glycosides as novel cancer therapeutic agents. Mol Interv. 2008;8(1):36–49.
   PubMedGoogle Scholar
• Prassas I, Diamandis EP. Novel therapeutic applications of cardiac glycosides. Nat Rev Discov. November 7, 2008;(11):926–935.
   Web of Science ®Google Scholar